This study consisted of 655 patients (75% males, mean age 60±13) with median follow-up of 9 months and median TIMI score of 4. 63.3% of the cohort had suboptimal HDL level <1.0mmol/L. Compared to those with HDL >1.0mmol/L, patients with HDL <1.0mmol/L were mostly male (p<0.001), Malay (p=0.05) or Indian (p=0.019). Patients with HDL <1.0mmol/L had more MACE at 6- (19.7% vs. 9.9%, OR 2.24 95%CI 1.16-4.33, p=0.016) and 9- months (28% vs. 16%, OR 2.07 95%CI 1.08-3.94, p=0.035). Adjusted analyses demonstrated increased risk of 1-month TVR among the Indians (4.8% vs. 0.6%, OR 8.85 95%CI 1.44-54.50, p=0.045) and 1-month nonfatal MI among the Malays (7.9% vs. 1.7%, OR 5.06 95%CI 1.31-19.52, p=0.038) with HDL<1.0mmol/L. 6-month MACE rates were higher among the Malays and Indians combined (23% vs. 13%, OR 2.04 95%CI 1.13-3.68, p=0.021) with HDL<1.0. Interestingly, Malays and Indians who had HDL >1.5mmol/L on admission appeared to have less MACE at 12 months compared to those who had HDL <1.0mmol/L (26% vs. 41%, OR 2.02 95%CI 1.02-4.01, p=0.06).